Cholecalciferol prevents low BMD in erythropoietic protoporphyria patients, reports research

A new study published in The Journal of Clinical Endocrinology & Metabolism showed that low bone mineral density (BMD) is more common in patients with erythropoietic protoporphyria (EPP) than in the general healthy population, however, BMD increases with cholecalciferol administration.

A rare hereditary metabolic condition of heme production is erythropoietic protoporphyria, which causes severe phototoxic responses that begin in childhood and last a lifetime. In order to prevent these responses, the patients wear sunblock and avoid the sun. Vitamin D insufficiency which is a known risk factor for early-onset osteoporosis, is increased by the EPP population's lack of sun exposure.

Since 2016, adult patients with EPP have been treated with afamelanotide, a strong synthetic analogue of α-melanocyte-stimulating hormone (α-MSH) that agonistically binds to the melanocortin-1 receptor (MC1R) to boost eumelanin synthesis. Furthermore, the effectiveness of cholecalciferol supplementation in raising BMD in the general population is still up for debate.

According to earlier research, the individuals with EPP had a significant frequency of osteoporosis. Thus, to determine the individuals at risk for low bone mineral density (BMD) and which factors (cholecalciferol and afamelanotide medication) increase BMD in EPP, Louisa Kluijver and colleagues carried out this study. This single-center, longitudinal, ambispective cohort study was conducted between 2012 and 2023, and 2-time surveys and patient data from adult EPP patients who had at least one dual-energy x-ray absorptiometry (DXA) scan were utilized.